Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer

OBJECTIVES:

Primary

• Determine the activity of gefitinib, in terms of median survival and distant metastatic disease control, in patients treated with neoadjuvant and adjuvant cisplatin, fluorouracil, and radiotherapy who are undergoing surgery for esophageal and gastroesophageal junction cancer.

Secondary

• Determine the pathologic complete and partial response rate in patients treated with this regimen.
• Determine the toxicity of this regimen in these patients and in patients who are disease free and receiving long-term maintenance gefitinib.

OUTLINE:

• Preoperative regimen: Patients undergo radiotherapy twice a day during days 1-12 (for a total of 10 treatment days). Patients receive fluorouracil IV continuously and cisplatin IV continuously on days 1-4. Patients also receive oral gefitinib once daily on days 1-28. At 6 weeks, patients with locoregionally confined disease undergo surgical resection and then proceed to the postoperative regimen. Patients with a medical contraindication to surgery proceed directly to the postoperative regimen.
• Postoperative regimen: Beginning 4-10 weeks after surgery or 6 weeks after completing the first course of therapy, patients undergo radiotherapy and receive fluorouracil and cisplatin as in the preoperative regimen.
• Maintenance regimen: Patients receive oral gefitinib beginning on day 1 of the postoperative regimen and continuing for 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 5 years.

PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed squamous cell carcinoma, adenocarcinoma, or large cell undifferentiated cancer of the esophagus or gastroesophageal junction

• T3, N1, or M1a disease only
• The following types are not allowed:

• Small cell undifferentiated carcinomas, lymphomas, or sarcomas
• Small cell or mixed small cell/non-small cell histology
• No evidence of distant hematogenous tumor metastases (M1b)
• No malignant pleural effusions

PATIENT CHARACTERISTICS:

Performance status

• ECOG 0-1

Life expectancy

• Not specified

Hematopoietic

• WBC > 3,500/mm^3
• Platelet count > 100,000/mm^3

Hepatic

• Alkaline phosphatase < 2 times normal
• AST < 2 times normal
• No unstable or uncompensated hepatic disease

Renal

• Creatinine ≤ 2.0 mg/dL
• Calcium normal
• No unstable or uncompensated renal disease

Cardiovascular

• No unstable or uncontrolled angina
• No unstable or uncompensated cardiac disease

Pulmonary

• See Disease Characteristics
• No limitations to pulmonary function that would preclude study participation
• No evidence of clinically active interstitial lung disease (asymptomatic patients with chronic stable radiographic changes are allowed)
• No unstable or uncompensated respiratory disease

Other

• Not pregnant or nursing
• Fertile patients must use effective contraception
• No evidence of severe or uncontrolled systemic disease
• No other uncontrolled malignancy
• No active infection
• No known severe hypersensitivity to gefitinib or any of its excipients

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No prior immunotherapy for this cancer

Chemotherapy

• No prior chemotherapy for this cancer

Radiotherapy

• No prior radiotherapy for this cancer

Surgery

• Recovered from any prior oncologic or other major surgery
• No prior surgical resection for this cancer
• No concurrent ophthalmic surgery

Other

• No prior photodynamic therapy for this cancer (prior laser treatments are acceptable)
• More than 30 days since prior unapproved or investigational drug
• No concurrent phenytoin, carbamazepine, barbiturates, rifampin, phenobarbital, or Hypericum perforatum (St. John's wort)